2344-17-4

Basic information

• Product Name: NSC56143
• Synonyms: NSC56143;[4,6-dichloro-2-(trifluoromethyl)pyrimidin-5-yl]amine;4,6-Dichloro-2-(trifluoromethyl)-5-pyrimidinamine
• CAS NO: 2344-17-4
• Molecular Formula: C₅H₂Cl₂F₃N₃
• Molecular Weight: 231.9906896
• Mol File: 2344-17-4.mol

Chemical Properties

• Boiling Point: 202℃
• Flash Point: 76℃
• Appearance: /
• Density: 1.711
• Vapor Pressure: 0.306mmHg at 25°C
• Refractive Index: 1.523
• PKA: -5.17±0.10(Predicted)
• CAS DataBase Reference: NSC56143(CAS DataBase Reference)
• NIST Chemistry Reference: NSC56143(2344-17-4)
• EPA Substance Registry System: NSC56143(2344-17-4)

Safety Data

• Hazardous Substances Data: 2344-17-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
NSC56143 is used as an anticancer agent for its ability to induce apoptosis in cancer cells by disrupting mitochondrial functions and causing oxidative stress. It also inhibits the growth and proliferation of cancer cells by interfering with the cell cycle and promoting DNA damage.
Used in Cancer Stem Cell Research:
NSC56143 is used as a research tool to investigate its potential to inhibit the growth of cancer stem cells, which are a subpopulation of cells within tumors that contribute to tumor progression and resistance to therapy. Understanding the effects of NSC56143 on cancer stem cells may lead to the development of more effective cancer treatments.
Used in Drug Development:
NSC56143 is used in the development of new cancer therapies, as its potential mechanisms of action and effects on various cellular processes are further studied. As a compound with demonstrated anticancer properties, it may serve as a basis for the creation of novel drugs or as a component in combination therapies to enhance the efficacy of existing treatments.

InChI:InChI=1/C5H2Cl2F3N3/c6-2-1(11)3(7)13-4(12-2)5(8,9)10/h11H2

Upstream product

• 652-62-0 5-nitro-2-trifluoromethyl-1H-pyrimidine-4,6-dione 
• 715-46-8 4,6-dichloro-5-nitro-2-trifluoro-methyl-pyrimidine 
• 672-47-9 2-trifluoromethyl-4,6-dihydroxypyrimidine 

Downstream Products

• 1305117-36-5 N₄-{[(2S)-4-Benzylmorpholin-2-yl]methyl}-6-chloro-2-(trifluoromethyl)pyrimidine-4,5-diamine 
• 1305117-37-6 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-7-chloro-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1305115-74-5 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-5-(trifluoromethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 
• 1305115-80-3 PF-04957325 
• 1397685-95-8 C₁₈H₁₉F₃N₆O 
• 1397685-90-3 C₁₈H₁₉F₃N₆O₂ 
• 1397685-89-0 C₁₆H₂₁F₃N₆O 

Relevant articles and documents

Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.

SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS

Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.